Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall

According to CNBC, Novo Nordisk's CEO defended the pill form of its Wegovy drug even as lower prices weigh on sales. Wall Street, though, isn't convinced the company can sustain growth while facing intensifying competition from Eli Lilly, and the stock fell on the news.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton